Related Experiment Video

Updated: Jul 4, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.2K

Human papilloma virus and atherosclerotic cardiovascular disease

Noel C Chan1, James S Lawson2, Jack Hirsh1

  • 1McMaster University, Hamilton, Ontario, Canada.

European Heart Journal
|February 6, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.5K

Related Experiment Videos

Last Updated: Jul 4, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.2K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.5K

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K

Articles linked to this work by shared authors, journal, and citation graph.

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026

A short history of anticoagulant therapy.

Thrombosis research·2026

Clinical and patient-reported outcomes after drug-coated balloon angioplasty for femoropopliteal peripheral artery disease.

VASA. Zeitschrift fur Gefasskrankheiten·2026

From bench to bedside: the untold story behind the clinical development of enoxaparin.

Journal of thrombosis and haemostasis : JTH·2026

Colchicine for secondary prevention of vascular events: a meta-analysis of trials.

European heart journal·2025

Anticoagulants: From chance discovery to structure-based design.

Pharmacological reviews·2025

Exercise stress echocardiography for diagnosis of heart failure with preserved ejection fraction: a multicentre study.

European heart journal·2026

Nighttime light exposure and cardiac structure and function.

European heart journal·2026

Subclinical liver disease and incident cardiovascular events.

European heart journal·2026

Reconciling evidence-based and personalized medicine: perspectives in heart failure and cardiomyopathies.

European heart journal·2026

Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

European heart journal·2026

Quality standards for preclinical research in cardio-oncology.

European heart journal·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us